AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01145417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin (Lyrica)
Description: 150 mg-600 mg/day (twice daily)
Study NCT02671578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: The N2O/O2 equipment was composed by two flow meters with an anti-hypoxia system valve, 70% N2O maximum disposal and 30 L/min O2 valve to immediate oxygen dispensation. Masks were individually selected, being 100% O2 (6 L/min) dispensed until respiratory rate stabilization. N2O was incremented at 10% each 2 minutes (70% max, if necessary) until some of the following signals were noticed: silence, relax/comfort report, decreased eyelid movements, decreased spontaneous body movements, warm sensation, tingling sensation or numbness at feet, hands or oral region, and slightly euphoric sensation.
Study NCT02435797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorandil
Description: All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the right (or left) femoral artery or radial artery using the Seldinger method.The guidewire was passed into the culprit lesion. Subjects in the NicorandilGroup were then given 2 mg intracoronary nicorandil through the lesions via thrombus aspiration catheter, and an additional intracoronary dose of 2 mg nicorandil before stent implantation. A minimum 5-min interval occurred between the first and second doses of nicorandil to reduce adverse effects.
Study NCT02435797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the right (or left) femoral artery or radial artery using the Seldinger method.The guidewire was passed into the culprit lesion. Normal saline in the Placebo Group were then given 2 ml through the lesions via thrombus aspiration catheter,and an additional intracoronary dose of 2 ml before stent implantation. A minimum 5-min interval occurred between the first and second injection.
Study NCT02435381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carisbamate
Description: 600mg Orally on days 2-4
Study NCT02435381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment only
Study NCT02156388 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GW003
Description: freeze-dried powder；single SC injection
Study NCT04239157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Given SC
Study NCT04585737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir / Lamivudine Pill
Description: Experimental
Study NCT04585737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill
Description: Active comparator
Study NCT02375932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-Visit Tool
Description: Patients receive a secure electronic message from their primary providers asking them to prepare for their visit by reviewing important areas of care and identifying their top priorities for discussion at a scheduled visit
Study NCT02375932 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Control
Description: Patients continue to receive usual care from their primary care provider
Study NCT00793299 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Illness Narrative
Description: video
Study NCT02499835 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02499835 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-HP Plasmid DNA Vaccine
Description: Given ID
Study NCT00666835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX575 epoetin alfa Hexal AG
Description: HX575 Solution for i.v. injection Containing 1000, 2000 and 4000 IU of rh erythropoietin
Study NCT00666835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ERYPO®, Janssen-Cilag
Description: Solution for i.v. injection
Study NCT03972137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Smoking Cessation
Description: Participants were provided with six individualized smoking cessation counseling sessions designed to help them prepare to quit, set a quit date, behaviorally manage early abstinence, and to resume cessation upon lapse.
Study NCT03972137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback (HRVB)
Description: All participants were provided with individualized training in resonance breathing using biofeedback to help improve self-regulation.
Study NCT03972137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine patch
Description: All participants were offered up to eight weeks of transdermal nicotine patch, beginning on their quit date.
Study NCT01906658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection
Description: Acthar given SC twice weekly (80 U or 56 U) or daily (24 U or 16 U) for 8 weeks
Study NCT00529555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minocycline HCl 2.1%
Description: Minocycline HCl 2.1% gel as an adjunct to scaling and root planing. Dosing is by topical delivery into gingival pockets at baseline, 2 weeks, 4 weeks, 3 months and 6 months.
Study NCT00529555 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Scaling and root planing
Description: scaling and root planing
Study NCT00529555 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: scaling and root planing
Study NCT03226353 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A
Description: contact lens
Study NCT03226353 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: omafilcon A
Description: contact lens
Study NCT03974451 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL implantation experimental
Description: Implantation of of PhysIOL trifocal FineVision® POD F IOL
Study NCT03974451 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOL implantation active comparator
Description: Implantation of the Abbott Medical Optics, Inc. Tecnis Symfony® IOL
Study NCT03317899 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo auto HSCT
Study NCT03317899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tbo-filgrastim
Description: Given subcutaneously
Study NCT03317899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative Studies
Study NCT03168425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored prescription
Description: Participants will be prescribed an opioid tablet number based on a formula derived from inpatient opioid use
Study NCT03168425 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Participants will be prescribed 30 tablets of oxycodone 5mg
Study NCT02747121 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: External inspection of health services
Description: The intervention is external inspections of acute hospitals addressing early detection and treatment of sepsis. The intervention is delivered on an organizational level. Individuals are not assigned to an intervention. The investigator use data from individuals to assess if the organizational intervention affects care. Therefore the investigator argues that that the study is observational. The inspection will have two components, a system revision and a follow up audit with verification of patient records 8 months later. The inspection can be considered a complex intervention. The study does not intend to evaluate the individual effects of the different components of the inspection, rather the effect of the inspection as a whole.
Study NCT02747121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: External inspection of health services
Description: The intervention is external inspections of acute hospitals addressing early detection and treatment of sepsis. The intervention is delivered on an organizational level. Individuals are not assigned to an intervention. The investigator use data from individuals to assess if the organizational intervention affects care. Therefore the investigator argues that that the study is observational. The inspection will have two components, a system revision and a follow up audit with verification of patient records 8 months later. The inspection can be considered a complex intervention. The study does not intend to evaluate the individual effects of the different components of the inspection, rather the effect of the inspection as a whole.
Study NCT04318587 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Allosure
Description: Blood is collected from the patient, packaged, and shipped at ambient temperature to CareDx for testing. Donor-derived cell-free DNA is measured via targeted amplification and sequencing of a set of carefully selected and validated SNPs. The AlloSure bioinformatics software calculates the percent dd-cfDNA in the sample tested and applies the QC criteria. The AlloSure results will be compared to the episodes of acute rejection diagnosed by transbronchial biopsy and BOS/CLAD diagnosed by spirometry in the subjects medical records. Transbronchial biopsies and spirometry are standard of care for lung transplant recipients.
Study NCT01639014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F2695
Description: 75 mg OD in 2 capsules
Study NCT01639014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 capsules
Study NCT01359514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 5 weeks
Study NCT01359514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 5 weeks
Study NCT02117856 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 1 implant placed surgically in the mandibular midline
Description: Participants receive an implant in the mandibular midline using a surgical flap procedure with local anaesthesia.
Study NCT02117856 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2 implants placed surgically in the mandibular canine sites
Description: Participants receive implants bilaterally in the site of the mandibular canines using a surgical flap procedure with local anaesthesia.
Study NCT02117856 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soft reline (Coe Comfort) of the existing complete lower denture
Description: Participants receive a soft reline of the existing complete lower denture approximately 10 days after placement of the implant(s).
Study NCT02117856 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2.25mm ball patrix placed on 1 healed implant
Description: A 2.25mm ball patrix is screwed onto the 1 implant approximately six weeks after placement of the implant.
Study NCT02117856 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2.25mm ball patrices placed on 2 healed implants
Description: 2.25mm ball patrices are screwed onto the 2 implants approximately six weeks after placement of the implants.
Study NCT02117856 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reline (Ivoclar acrylic-resin) with 1 retentive matrix in the lower denture
Description: Participants have their complete lower denture relined with a laboratory-processed acrylic resin to incorporate 1 retentive matrix in the denture-base to retain on the implant.
Study NCT02117856 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reline (Ivoclar acrylic-resin) with 2 retentive matrices in the lower denture
Description: Participants have their complete lower denture relined with a laboratory-processed acrylic resin to incorporate 2 retentive matrices in the denture-base to retain on the implants
Study NCT02503306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVANAFIL
Description: Pharmaceutical form:tablets Route of administration: oral
Study NCT02503306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form:tablets Route of administration: oral
Study NCT00912054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DuoTrav APS
Description: travoprost APS 40 micrograms/ml / timolol 5 mg/ml, Eye Drops, Solution, once daily
Study NCT00912054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xalacom
Description: XALACOM® (latanoprost 50 micrograms/ml / timolol 5 mg/ml) Eye Drops, Solution
Study NCT03275402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 131I-omburtamab
Description: Murine IgG1 monoclonal antibody radiolabeled with iodine-131
Study NCT02399683 — intervention group
Intervention type: BIOLOGICAL
Intervention: Trichuris trichiura eggs
Description: Live eggs from human whipworm, Trichuris trichiura
Study NCT01537900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: GZR 100 mg tablet by mouth q.d. for 7 days.
Study NCT04836338 — intervention group
Intervention type: DEVICE
Intervention: orotracheal intubation
Description: orotracheal intubation
Study NCT01797705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DeVilbiss AutoAdjust CPAP with revised algorithm
Description: Subjects attended a one-night polysomnogram (PSG) titration study. DeVilbiss AutoAdjust CPAP with a revised algorithm was compared to hand-scored PSG to determine whether the machine results were equivalent to hand scores. Each subject acted as their own control for assessing accuracy of sleep event analysis and prescribed CPAP pressure.
Study NCT04059497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise condition
Description: Each participant in the intervention group can freely choose a handgrip of strength from 10 to 25kg which can be gripped with adequate grip strength. The PI will play the short video (5 minutes, www.youtube.com/watch?v=mZex2Wwy3fU) about the 10s-E for the participant, including (1) rapid grip-and-release the handgrip for at least 30 times in 10seconds in each hand, and (2) short-bout hand pushing and pulling exercises without handgrip. During the video, participants are asked to follow the 10s-E demonstrated by the medical professor. After the video, the PI will guide the participant to repeat the 10s-E for 5 times within the next 5 minutes. If participants feel pain in their hands, they can slow down the exercise. Between each exercise set, rest time for 10-20 seconds will be allowed. After practicing all these exercises, participants are asked to complete a post-intervention questionnaire
Study NCT04059497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy diet condition
Description: The control group will watch two videos on healthy diet (https://www.youtube.com/watch?v=w_u4BYV2Okc). Similar to the 10s-E condition, they will complete a post-intervention questionnaire after the two videos.
Study NCT01176435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa
Description: Solution taken orally three times a day.
Study NCT01176435 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution taken orally three times a day.
Study NCT02650726 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anthocyanin
Description: anthocyanin 320 mg daily for 24 weeks
Study NCT02650726 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 320mg daily for 24 weeks
Study NCT01940523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Tranexamic Acid
Description: 3 vials of tranexamic acid (1g tranexamic acid in 10cc each) must be mixed in the operating room by the team at the start of surgery with 45cc of saline solution (for a total of 3g tranexamic acid in 75mL solution). This solution will be applied to the open joint surfaces with two 60mL syringes (one with 60mL and one with 15m). The solution will be left in contact with the tissues for five minutes. The surgeon will suction away excess solution. The site may be irrigated before or after the tranexamic acid bath as long as the solution is in contact for at least five full minutes. After that, the tourniquet will be released and the rest of the surgery will proceed according to the standard of care.
Study NCT01940523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Tranexamic Acid
Description: 1 vial (1g of IV tranexamic acid in 10mL solution) will be administered prior to inflation of the tourniquet. A second 1g dose of IV tranexamic acid will be given during initiation of the closure after the tourniquet is deflated and during closure.
Study NCT03907254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Service Dog Training Program
Description: Participants will spend one hour, two times a week working with professional service dog trainers in order to shape the dog's behavior for it's future role as a service dog for service members with mobility impairments.
Study NCT02018471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducative training
Description: The Psychological education was inspired by the technique, Systematic Desensitization (SD), a therapeutic procedure that seeks to eliminate fear and avoidance behaviour
Study NCT03919318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Root Canal Filling Sealers
Description: Root Canal Obturation
Study NCT00902226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Flexible-dosed (5 to 20 mg Oral Tablets Daily)
Study NCT03122483 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood biomarker
Study NCT01049984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline
Description: 1mg tablet daily for 18 weeks
Study NCT01049984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet daily for 18 weeks
Study NCT03194854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fun For Wellness (FFW)
Description: FFW consists of videos, games, and content teaching 14 skills to support seven drivers of change that promote well-being in I COPPE domains. The drivers form the acronym BET I CAN, which stands for: Behaviors, Emotions, Thoughts, Interactions, Context, Awareness, and Next Steps. B teaches basics of habit formation, including antecedents, behaviors, and consequences and techniques like goal setting, behavior tracking and rewards. E teaches how to build positive emotions and cope with negative ones. T teaches lessons from cognitive behavioral therapy. I builds communication skills such as empathy, listening and assertiveness. C teaches how to create healthier environmental contexts. A aims to increase insight. N emphasizes the need to make plans and anticipate barriers.
Study NCT01271036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Formula PD-F-7716
Description: Apply a dime-size amount on each application site as instructed during the 1-week study period
Study NCT02512861 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:~Under 20kgs weight: 0.25% Bupivacaine at 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5% Bupivacaine at 0.5 ml/kg up to a maximum of 25ml of 0.5% Bupivacaine for patients > 50 kgs
Study NCT02512861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:~Under 20kgs weight: 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5 ml/kg up to a maximum of 25ml for patients > 50 kgs
Study NCT03730311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elpida
Description: elsulfavirine, capsules
Study NCT03730311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study NCT02254681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT02254681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT02254681 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low dose radiotherapy
Description: Whole liver and portal lymph node basin low dose radiotherapy
Study NCT04237129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gan & Lee Insulin Aspart
Description: All three IMPs will be administered as a 0.2 U/kg single dose subcutaneously in the periumbilical area.
Study NCT02685007 — intervention group
Intervention type: OTHER
Intervention: Tachosil
Description: TachoSil is a collagen matrix that is coated with human fibrinogen and human thrombin.
Study NCT03391583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Participants in the education arm of the study will be provided with three PowerPoint presentations. Material for these slides has been adapted from material developed by the Ontario Neurotrauma Foundation. Topics to be addressed will surround post-traumatic headache and will include information regarding common symptoms, timeline for improvement, red- flags and when to seek medical attention
Study NCT01930877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine iv bolus followed by infusion